開 拓 藥 業 有 限 公 司 * KINTOR PHARMACEUTICAL LIMITED （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股 份 代 號：9939） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 自願公告 就KT-939與上美股份簽訂戰略合作框架協議 本公告由開拓藥業有限公司*（「本公司」，連同其附屬公司統稱「本集團」）自願 刊發，以知會本公司股東及潛在投資者有關本集團的最新進展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，近日，本公司全資附屬公司蘇州 開拓藥業股份有限公司（「蘇州開拓」）與上海上美化妝品股份有限公司（一家於 香港聯合交易所有限公司上市的公司（股份代號：2145），「上美股份」）訂立化 妝品領域附帶排他條款的戰略合作框架協議（「框架協議」），內容有關本公司 美白祛斑功效性化妝品原料KT-939的快速商業化。 根據框架協議，蘇州開拓與上美股份就KT-939在中國作為一種化妝品新成分 的註冊與 ...

Core Viewpoint - The company clarifies that its cosmetic sales business, while providing opportunities for commercialization, is currently small in scale compared to its core pharmaceutical business, which focuses on the development and commercialization of KX-826 and GT20029 [1] Group 1: Product and Sales - The product in question is a foam agent for hair loss under the KOSHIN brand, primarily featuring KX-826 as its main ingredient [1] - The company sets a long-term sales target of RMB 100 million, which is cumulative and not expected to be achieved in the short term [1] Group 2: Human Resources - As of the announcement date, the company has 121 employees, with 69 dedicated to drug research and supply, and 24 focused on cosmetic sales and marketing preparations for candidate drugs [1] Group 3: Financials and Funding - R&D expenses are projected to account for over 50% of total expenditures until December 31, 2025, primarily due to funding for KX-826's clinical trials for androgenetic alopecia and GT20029's clinical trials for acne [1] - The board confirms that cash flow from the cosmetic business will be utilized to fund medical and biological applications and development [2] - The company is actively negotiating bank financing expected to be granted in Q1 2026 and is also seeking equity financing from potential investors [2]

Group 1 - The company has clarified that its anti-hair loss foam product, KX-826, is part of its KOSHINÉ cosmetics brand and that the sales target of RMB 100 million is a long-term goal rather than a short-term sales expectation [1] - The cosmetics sales business is currently small and auxiliary compared to the company's core business of drug development and commercialization [1] - As of the announcement date, the company has 121 employees, with 69 dedicated to drug research and supply, and 24 focused on cosmetics sales and marketing [1] Group 2 - The board has confirmed that the cash flow from the cosmetics business will be used to fund medical and biological applications and development [2] - The company is actively negotiating bank financing expected to be granted in the first quarter of 2026 and is also seeking equity financing from potential investors [2] - The board believes that the company's financial resources and liquidity are sufficient to support its operations, research, and commercialization of core products [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 開 拓 藥 業 有 限 公 司 * KINTOR PHARMACEUTICAL LIMITED （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股 份 代 號：9939） 有關自願公告的補充公告 茲提述日期為2026年1月21日的自願公告（「該公告」）。除文義另有所指外，本 公告所用詞彙與該公告所界定者具有相同涵義。 董事會謹此提供進一步資料說明，防脫泡沫劑產品（「該產品」）為本公司化妝 品品牌KOSHINÉ旗下以KX-826為主要成分的產品之一。本公司謹此澄清，儘 管銷售代理協議為進一步推動本公司化妝品商業化提供了有利機會，但與本 集團的上市業務（即本公司核心產品KX-826及GT20029及其他管線產品的開發 及商業化）（「上市業務」）相比，該化妝品銷售業務目前規模較小，屬輔助性質。 謹此說明，該公告所披露的人民幣100百萬元銷售目標是按累計基準計量的長 期目標，而非預期於短期內達致 ...

Group 1 - The company reported an increase in revenue from RMB 0 million to RMB 6.0 million for the six months ending June 30, 2025, primarily driven by global sales of its new high-end cosmetics brand KOSHINé [1] - Research and development costs rose by RMB 9.3 million or 23.6% from RMB 39.3 million for the six months ending June 30, 2024, to RMB 48.6 million for the six months ending June 30, 2025, due to a focus on core dermatology pipelines KX-826 and GT20029 [1] - The company has five potential first-in-class/best-in-class drug candidates in clinical stages I-III and one new whitening ingredient KT-939, with significant progress in clinical trials for KX-826 and GT20029 in China [1] Group 2 - The company is in a transitional phase from research and development to commercialization of its cosmetics, planning to allocate more resources to explore various methods, including launching new products and increasing promotion in both domestic and overseas markets [2] - Future strategies include deepening partnerships with leading e-commerce platforms such as Tmall, JD.com, Douyin, Xiaohongshu, and Amazon, and establishing a diversified sales channel system [2] - The company aims to enhance customer resource expansion and loyalty through various promotional activities and refined membership management, including hosting exclusive member events and collaborating with selected KOLs and KOCs to accelerate online sales growth [2]